原文摘录：See all DONs related to this event Read more about Ebola disease Situation at a glance Since the publication of the previous Disease Outbreak News on 23 October 2026, the Bundibugyo virus disease (BVD) outbreak has expanded geographically in the Democrati … item/2026-DON625
原文摘录：Comirnaty RSS Authorised This medicine is authorised for use in the European Union COVID-19 mRNA vaccine Medicine Human Authorised Rolling review Application under evaluation CHMP opinion European Commission decision Overview Comirnaty is a vaccine for pr … 5-containing Covid-19 mRNA vaccines in the Nordic countries - post-authorisation study A Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Recipients of the Pfizer-BioNTech COVID-19 mRNA vaccine in the EU - post-authorisation study Real-world effectiveness of different COVID-19 vaccines in Spain: a cohort study based on public electronic health records (BIFAP) (effectiveness of COVID-19 vaccines in Spain) - post-authorisation study This page was last updated on 06/11/2026
WHO候选疫苗优先技术咨询小组基于现有临床前和早期临床证据，建议将牛津大学与印度血清研究所的ChAdOx1及Moderna的mRNA-1469加入刚果（金）Tumaini试验，系针对Bundibugyo病毒的疫苗首次在疫情期间接受临床评估，待国家批准后入组。
关注理由：针对Bundibugyo病毒的候选疫苗首次在疫情期间进入临床评估，Tumaini多疫苗试验与治疗研究并行推进，结果时间表明确，可跟踪疫情期间疫苗评价模式的验证进展。
Merck与Moderna公布intismeran autogene联合Keytruda治疗黑色素瘤术后患者的III期中期结果：中位随访两年，联合组复发或死亡风险较Keytruda单药降低42%，两年未复发率为82.2%对70%，主要终点无复发生存期达到。
关注理由：该评论将泄露后公布的III期中期数据与II期结果及Keytruda单药两年基线对照，指出总生存期尚未成熟、膀胱癌与肾细胞癌数据未读出，有助于把疗效信息与资本市场波动分开看待。